Clinical trial
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's…
NCT00131937 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00131937 |
|---|---|
| Title | Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 14 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2011 |
| Completion | Aug 1, 2012 |
| First posted | Aug 19, 2005 |
| Last update posted | Sep 3, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: